The Year in Heart Failure  by Tang, W.H. Wilson & Francis, Gary S.
YT
W
C
H
d
m
a
F
H
m
s
N
D
T
s
a
b
d
s
i
p
t
t
b
D
r
u
w
p
“
O
O
N
t
a
N
t
b
i
C
N
G
H
G
f
D
c
Journal of the American College of Cardiology Vol. 46, No. 11, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PEAR IN CARDIOLOGY SERIES
he Year in Heart Failure
. H. Wilson Tang, MD, FACC, Gary S. Francis, MD, FACC
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.018leveland, Ohio
d
m
a
p
f
m
(
(
y
e
H
B
(
H
(
t
i
p
a
a
t
H
n
m
p
E
n
r
s
r
(
h
f
w
p
s
m
t
c
a
s
t
c
i
teart failure continues (HF) to be prevalent, costly, and
ifficult to treat despite much emerging data. This year’s
ajor developments involve promising refinement of our
bility to detect, monitor, and risk stratify patients with HF.
urthermore, results from several proof-of-concepts trials in
F therapeutics have been presented or published, which
ay lead to the clinical development of newer treatment
trategies.
EW UNDERSTANDING OF
ILATED CARDIOMYOPATHY (DCM)
here have been important contributions in our under-
tanding of the pathogenesis of DCM that are clinically
pplicable. Gene expression profiling may have demonstra-
le differences between ischemic versus non-ischemic car-
iomyopathy (1). Recent evaluation of myocardial biopsy
pecimens reveal that over two-thirds of patients with
diopathic DCM have evidence of viral genome (2), and
articularly parvovirus B19 (3). Furthermore, several muta-
ions common to hypertrophic cardiomyopathy were found
o be prevalent in familial DCM (such as troponin T and
eta-myosin heavy chain) (4,5). Treatable asymptomatic
CM can be identified in as many as 4.6% of asymptomatic
elatives of patients with cardiomyopathy (6). With this new
nderstanding, effective genetic and screening strategies
ould be helpful to better distinguish the cardiomyopathic
henotype from what would otherwise be considered as
idiopathic.”
BJECTIVE QUANTIFICATION
F CLINICAL STATUS IN HF
atriuretic peptides. The popularity of using B-type na-
riuretic peptide (BNP) or aminoterminal pro-BNP as an
id to the diagnosis of HF continues to increase in 2005.
ew evidence has also suggested that BNP may not be so
ightly coupled to hemodynamic alterations as previously
elieved (7–9). Natriuretic peptides have also been utilized
n new settings beyond the diagnosis of patients with acute
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yocardial ischemia (11). In contrast, there has been further
ppreciation of possible confounders of plasma natriuretic
eptide levels beyond established confounders (e.g., renal
unction, assay types, and demographics), including body
ass index (lower levels with obesity) (8), hemoglobin
higher levels found in anemia) (12), and coronary ischemia
higher levels with ischemia) (11,13).
Natriuretic peptides will likely provide information be-
ond diagnosis and prognosis of HF (14). Perhaps the most
xciting development was the announcement of the Systolic
eart Failure Treatment Supported by BNP (STARS-
NP) trial results at the American College of Cardiology
ACC) scientific session, where a BNP-guided strategy of
F management resulted in improved clinical end points
15). Several novel biomarkers have also emerged this past year
o provide good prognostic values in patients with chronic HF,
ncluding cardiac troponins (16), high-sensitivity C-reactive
rotein (17), erythropoietin (18), urocortin-1 levels (19), and
diponectin (20) to name a few. Whether these biomarkers
re concordant risk markers or genuine risk factors remains
o be determined.
emodynamic assessment. This year marked the an-
ouncement of several landmark clinical studies using he-
odynamic assessment to guide clinical management of
atients with acute and chronic HF. First, results from the
valuation Study of Congestive Heart Failure and Pulmo-
ary Artery Catheterization Effectiveness (ESCAPE) have
ecently been published (21). In the ESCAPE trial, 433
ubjects admitted with acute decompensated HF were
andomized to receive either pulmonary artery catheter
PAC)-guided therapy or usual care. The patient population
ad rather advanced HF (mean left ventricular ejection
raction [LVEF] 19%, serum creatinine 1.5 mg/dl, 6-min
alk 400 feet). At the end of six months, the primary end
oint of “total number of days patients are well” did not
how any differences between the two groups (21). Overall
ortality at six months was similar at 19%. This prospec-
ive, randomized controlled trial may have laid to rest
oncerns that use of PAC in patients with advanced HF is
ssociated with increased death and hospitalization. At the
ame time, the ESCAPE study investigators also suggest
hat PAC should not be used routinely to guide therapy; the
omplication rate was 4%, and outcomes were not clearly
mproved due to PAC monitoring. Despite the neutrality of
he primary end point, post-hoc analysis suggests that when
ompared with conventional management, PAC-guided
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The Year in Heart Failure December 6, 2005:2125–33herapy may lead to better preservation of renal function,
ore use of vasodilators and less use of thiazides, and
rescription of significantly smaller doses of loop diuretics
pon discharge (22). There is a growing recognition that use
f large doses of diuretics used chronically for stable HF
ay be imprudent.
Meanwhile, new implantable devices to measure intra-
ardiac hemodynamic variables are emerging, and the pro-
otype device, Chronicle (Medtronic Inc., Minneapolis,
innesota) was put to the test in the Chronicle Offers
anagement to Patients With Advanced Signs and Symp-
oms of Heart Failure (COMPASS-HF) study. Preliminary
esults of this six-month randomized, single-blind study
ere presented at the ACC Annual Scientific Sessions in
005(23). This study demonstrated statistically significant
eductions in all-cause mortality and mortality plus hospi-
alizations in the group randomized to optimal medical care
uided by the Chronicle device (n  134) versus optimal
edical care alone (control, n  140). The use of the
mbulatory monitoring device in addition to optimal ther-
py was associated with a 22% reduction in overall HF-
elated events and decreased worsening HF by 33% com-
ared with optimal therapy alone. Furthermore, in a subset of
ew York Heart Association (NYHA) functional class III
atients, the use of the Chronicle reduced the rate of heart-
ailure-related events by 41%. However, widespread adoption
f remote hemodynamic monitoring will need innovative
trategies for data compression and effective integration into
veryday clinical practice, without overburdening the busy
ealth care providers.
Impedance is a measure for the manner and degree a
omponent resists the flow of electrical current if a given
oltage is applied, and can be applied to assess the degree of
otal body or pulmonary edema in the HF patient. There
as been accruing evidence that measuring impedance may
e a valuable tool for risk stratification of patients with HF.
here have been over 500 publications in the literature
egarding the use of impedance measurements in cardiology,
ut many of these studies relied on crude correlative
tatistics and observational studies. This has been compli-
ated by the fact that there are many different proprietary
lgorithms to detect impedance, and several variables may
ffect the reliability of the results (such as body habitus and
lectrode positioning). The lack of a “gold standard” of
ardiac decompensation also poses validation problems.
ike BNP, the clinical significance and application of data
erived from impedance measurements will likely need
ndependent research beyond correlation with standard
emodynamic measures. Preliminary results of the 212-
atient Prospective Evaluation of Cardiac Decompensation
n Patients with Heart Failure by Impedance Cardiography
est (PREDICT) trial (24) illustrate for the first time the
bility of three variables from the BioZ (CardioDynamics
nc., San Diego, California) impedance cardiography (tho-
acic fluid content index, velocity index, and left ventricular
jection time) to risk stratify outpatients with HF. However, fike the Chronicle, much work is still needed to provide
alidation and guidance to effectively incorporate impedance
ardiographic information into clinical practice.
A new concept has emerged after the approval of a device-
ased intrathoracic impedance measurement technique. This
ew device is capable of generating daily averages of
ntrathoracic impedance measurements from the right ven-
ricular lead of the cardiac resynchronization system (InSync
entry, Medtronic Inc.). Recent data demonstrate the
romise of this technique for early detection and prediction
f HF decompensation and progressive fluid retention using
derived index of intrathoracic fluid accumulation (25).
ith the broad adoption of device therapies for patients
ith HF, wider applications of device-based remote mon-
toring strategies will continue to evolve. It remains to be
een how such additional information will be used and
hether it will be translated into better outcomes.
ISEASE MANAGEMENT IN HF
he traditional path of HF drug development has relied
pon positive results from randomized controlled trials to
eliver significant morbidity and mortality benefits. How-
ver, the incremental benefit of add-on drug therapy has
een diminishing, and, therefore, several current strategies
o improve HF outcomes have focused on improving
elivery and organization of care. A large randomized
ontrolled trial suggests that participation in a HF disease
anagement program results in a significant long-term
urvival benefit, most notably in symptomatic systolic HF
atients (26). Nurse-driven HF disease management inter-
ention delivered uniformly across a diverse provider system
f a well-treated patient population can still reduce hospi-
alization rates (27,28). However, disease management pro-
rams may not improve objective measures of functional
apacity and may not reduce cost and health care utilization.
n contrast, the addition of pre-discharge teaching session
an result in improved clinical outcomes, increased self-care
easure adherence, and reduced cost of care in patients with
ystolic HF (29).
Quality improvement initiatives were highlighted with
he launching of the ACC/American Heart Association
AHA) Get-with-the-Guidelines initiative and the quality
nd clinical performance measures from the Joint Commis-
ion on Accreditation of Healthcare Organizations and
CC/AHA (30,31). When surveyed across hospitalized
atients with decompensated HF, there is significant indi-
idual variability in conformity to quality-of-care indicators
nd clinical outcomes and a substantial gap in overall perfor-
ance (32). Adherence of physicians to HF treatment guide-
ines has shown to be a strong predictor of fewer cardiovascular
ospitalizations in actual practice in Europe (33).
Managing comorbidities continues to be a popular topic.
everal outcomes research groups reported on the potential
enefits of insulin sensitizers (thiazolidinediones and met-
ormin) in elderly diabetic patients after HF hospitalizations
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December 6, 2005:2125–33 The Year in Heart Failure34) or acute myocardial infarction (35). Diuretic use and
enal insufficiency remain the focus of several ongoing
esearch studies in acute HF. Anemia has also been a widely
iscussed therapeutic target in HF, as baseline and changes
n hemoglobin over 12 months have been shown to be
nversely associated with subsequent risk of mortality and
orbidity, independent of other important predictors (36,37).
ognitive impairment and depression have also become more
idely recognized in the HF population (38,39).
EFINING PHARMACOLOGIC THERAPY IN HF
ew guidelines for HF therapy. While the focus of HF
herapy remains neurohormonal blockade and volume man-
gement, several exciting new paradigms in HF manage-
ent have emerged during the past year. This year also
itnessed the publication of new American guidelines for
he management of chronic HF (40) and new European
uidelines for both acute and chronic HF (41,42). The
CC/AHA guidelines have preserved and refined the
oncept of the four stages of HF presented in 2001, with
tages A and B designated patients “at risk for HF” and
tages C and D including patients with symptomatic HF.
tage A now includes obesity as a risk factor for the
evelopment of HF. Additional changes include recom-
endations for secondary prevention in stages A and B
atients with atherosclerotic vascular disease, control of
lood sugar in diabetic patients, and non-invasive evaluation
f cardiac function in patients with a strong family history of
ardiomyopathy or in those receiving cardiotoxic drugs.
ollow-up visits should include assessment of activities of
aily living, volume status and weight, use of cardiotoxic
rugs and therapies, and potential causative factors. How-
ver, routine serial measurements of plasma natriuretic
eptides still cannot be recommended at this time. Angio-
ensin II receptor blockers (ARBs) are now a reasonable
lternative to angiotensin-converting enzyme (ACE) inhib-
tors as first-line agents for HF. Angiotensin II receptor
lockers or ACE inhibitors are useful to prevent HF in
elected stage A and B patients, and candesartan can
mprove outcomes in patients with impaired cardiac func-
ion who are intolerant of ACE inhibitors. Digitalis has
een downgraded from the 2001 guidelines from a class I to
class IIa recommendation. Addition of an aldosterone
eceptor antagonist is reasonable in selected patients with
oderate-to-severe symptoms of HF and reduced LVEF or
n the post-infarction setting, and should be given to those
ho can expect to have renal function and serum electrolytes
arefully monitored. The use of combination hydralazine
nd nitrates for stage C patients with impaired LVEF who
re intolerant of ACE inhibitors and/or ARBs is now class
Ib, as is the addition of an ARB to persistently symptom-
tic patients with reduced LVEF who are already being
reated with conventional therapy. The recommendations
or implantable cardioverter-defibrillators (ICDs) have been
xtensively expanded. Recommendations from the Euro- gean guidelines for chronic HF are generally concordant in
he overall approach, although there may be some differences in
ow the guidelines construct their final recommendations.
eurohormonal antagonists in chronic HF. Data con-
inue to be robust with regard to the role of renin angio-
ensin aldosterone system blockade for reverse cardiac re-
odeling, particularly in the setting of post-infarction
emodeling. Reverse remodeling continues to be an excel-
ent surrogate marker for long-term outcomes. This is best
emonstrated with the similar changes in myocardial geom-
try of the three treatment groups that paralleled their
quivalent outcomes in the Valsartan in Acute Myocardial
nfarction trial (VALIANT) (43). Furthermore, results of
he Reversal of Ventricular Remodeling with Toprol XL
REVERT) study presented at the recent Heart Failure
ociety of America Annual Scientific Sessions also pointed
o a dose-dependent improvement in left ventricular struc-
ure and performance with metoprolol succinate therapy
ven in the asymptomatic setting (44).
The sequence of initiation for neurohormonal antagonists
as been re-examined (45). The traditional view of starting
herapy with ACE inhibitor/ARB has been further chal-
enged in the Third Cardiac Insufficiency Bisoprolol study
CIBIS-III) (46). This study randomized two strategies of
rug initiation (enalapril first, then bisoprolol vs. the reverse
rder) in 1,010 elderly subjects with chronic HF (LVEF
40%, NYHA functional class II to III) and found non-
nferiority between the two strategies on long-term mortal-
ty. Because polypharmacy continues to be a problem for
atients with HF, such re-evaluation of treatment strategies
s an attempt to individualize drug therapy.
CHIEVING NITRIC OXIDE (NO) BALANCE IN HF
erhaps one of the most important new concepts in HF
ver the past year has been the recognition of the impor-
ance of nitric oxide (NO) in patients with acute and
hronic HF. The role of NO in HF has been unclear over
he past decade, and the pros and cons of oxidative stress
nd the relative contributions of NO/redox pathways have
rovided a dizzying array of hypotheses that continue to be
ebated in the basic science arena. However, results of
everal new clinical trials have established the need to move
his debate to human studies.
O donors. The early termination and the publication of
he African American Heart Failure Trial (A-HeFT)
parked a debate about the role of NO donor therapy and
he concept of race as a surrogate for pharmacogenetic
ifferentiation. Studying only symptomatic African American
atients with chronic HF, the A-HeFT study demonstrated a
% absolute reduction in mortality with add-on hydralazine-
sosorbide dinitrate combination (BiDil, NitroMed Inc., Lex-
ngton, Massachusetts) (47), with accompanying modest
ntiremodeling effects. These results are astonishing, but it
s important to note that the mortality curves of the two
roups do not diverge until after the first six months of
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The Year in Heart Failure December 6, 2005:2125–33herapy (Fig. 1), even though the HF hospitalization curves
iverge earlier on. There have been several assumptions that
ere made in this otherwise very well-designed study. First,
he role of baseline blood pressure in this somewhat hyper-
ensive population has been adjusted statistically, but the
ontribution of blood pressure lowering effects of BiDil is
pparent. Also, the emphasis of these beneficial results has
een attributed to the NO donor properties of isosorbide
initrate. Certainly, this study has raised the discussion about
he use of race to target therapeutic responses, but there is a
aucity of mechanistic evidence in humans because NO is
ifficult to measure directly in patients with HF.
Meanwhile, other methods to enhance NO donor prop-
rties, such as nebivolol, also show benefit in patients with
F. Nebivolol is a novel beta-adrenergic blocking drug with
O-donating properties. The study of the Effects of
ebivolol Intervention on Outcomes and Rehospitalisation
n Seniors With Heart Failure (SENIORS) trial, random-
zing nebivolol versus placebo in elderly patients with HF,
lso demonstrated a 12% relative risk reduction in all-cause
ortality and a 14% relative reduction in mortality plus HF
ospitalizations (48). While some critics may frown on the
elatively less robust mortality benefits in comparison with
ther beta-blocker mortality trials, it is important to recog-
ize that this is one of the few large-scale mortality trials
hat focuses on treating HF in the elderly population.
O synthase inhibitors. At the other end of the spectrum,
verzealous production of NO under inflammatory and
xidative stress has recently been implicated in the devel-
pment of hypotension seen in cardiogenic shock after acute
oronary syndromes. Tilarginine acetate is a synthetically
roduced endogenous small molecule, NG-monomethyl-l-
rginine monoacetate (L-NMMA), which inhibits the pro-
uction of NO. Data from a phase II dose-ranging study
ith intravenous L-NMMA infusion were presented at the
Figure 1. Primary results of the African American HearHA meeting in November 2004 (49). The study found Bhat tilarginine was well tolerated, and the survival findings
ere encouraging, particularly in those tolerating the high-
st doses of tilarginine. A phase III trial, Tilarginine Acetate
or Injection in a Randomized International Study in
nstable Acute Myocardial Infarction Patients with Car-
iogenic Shock (TRIUMPH), is now underway.
ENAL PRESERVATION IN ACUTE HF
he Acute Decompensated Heart Failure National
ADHERE) registry. The importance of renal function
reservation in the treatment of acute decompensated heart
ailure (ADHF) have long been recognized, but has recently
een catalyzed by several observations from a national acute
F registry. Fonarow et al. (32) utilized the ADHERE
egistry to estimate the mortality risk in patients hospital-
zed with acute decompensated HF. A total of 33,046
ospitalizations (derived cohort) were validated and ana-
yzed. The best single predictor for mortality was high
dmission levels of blood urea nitrogen (43 mg/dl [15.35
mol/l]), followed by low admission systolic blood pressure
115 mm Hg) and high levels of serum creatinine (2.75
g/dl [243.1 mol/l]). These predictors emphasize the
mportance of preserving renal function in patients with
cute decompensated HF. We can look forward to new
trategies to better understand the important role of volume
tatus and titration of diuretic therapy in the development of
he grave cardio-renal syndrome.
esiritide and other vasodilators. Two post-hoc analyses
y Sackner-Bernstein et al. (50,51) have introduced the
ossibility that nesiritide may be associated with the devel-
pment of renal dysfunction (50) and heightened mortality
51) (Table 1). A panel of experts was assembled under the
eadership of Dr. Eugene Braunwald to further investigate
nd report on nesiritide use in the context of the Sackner-
ure trial (A-HeFT). Reproduced with permission (47).ernstein observations. The panel made a number of
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December 6, 2005:2125–33 The Year in Heart Failuremportant recommendations including: 1) use of nesiritide
hould be limited to patients who are hospitalized with
cute decompensated HF; and 2) nesiritide should not be
sed for intermittent outpatient infusion, for scheduled
epetitive use, to improve renal function, or to enhance
iuresis (52). The use of nesiritide to treat outpatients with
hronic HF should be restricted to an ongoing randomized
rial, Follow Up Serial Infusions Of Natrecor (FUSION II).
uestions about the use of nesiritide to treat chronic HF
emain, but some clarification is expected from the FU-
ION II trial, which has enrolled about one-half of its
arget sample at the time of this writing.
Meanwhile, several new vasodilator/natriuretic peptides
re under clinical development for possible use in the acute
ecompensated HF setting. The early termination of Value
f Endothelin Receptor Inhibition with Tezosentan in
cute Heart Failure Studies (VERITAS) was a disappoint-
ent that contributes to a long line of unsuccessful attempts
o demonstrate efficacy of endothelin receptor blockade in
atients with HF (53). The role of endothelin receptor
lockers in pulmonary and systemic hypertension is still
nder study. What is intriguing is that while the acute
emodynamic effects of tezosantan are undisputed, the
linical outcome measurements are unimpressive. The study
akes the point that it is difficult to find adequate clinical
nd points for acute decompensated HF trials. Even the
uantitative measurement of dyspnea remains problematic.
he questions of how to measure clinical end points and
xactly which clinical end points to measure in patients
ith acute decompensated HF remain elusive. This will
ertainly be challenging for several upcoming vasodilating
atriuretic peptide drugs (such as carperitide and ularit-
de) and aquaretic agents/devices (such as tolvaptan and
ltrafiltration).
ONTINUING CHALLENGES TO
EVELOP NOVEL THERAPIES IN HF
nodilator therapy. Over the past few years, a large clinical
evelopment program with the drug, enoximone, a phos-
hodiesterase inhibitor, yielded promising preliminary re-
ults during an era of concomitant cardioprotection with
eta-blockers and ICDs. The phase II results of Oral
noximone in Intravenous Inotrope-Dependent Subjects
EMOTE) demonstrated promise (54). However, the phase
II Studies of Oral Enoximone Therapy in Advanced Heart
ailure (ESSENTIAL) trials were recently presented in the
able 1. Meta-Analysis of 30-Day Mortality Risk and Risk of D
Tri
nadjusted 30-day mortality NSGET, VMA
orsening renal function VMAC, PREC
orsening renal function requiring
medical intervention
325, 326
orsening renal function requiring dialysis VMAC, 325, 3
I  confidence interval; HR  hazard ratio.005 European Society of Cardiology Congress and dem- tnstrated a lack of statistically significant differences in all
redefined end points (55). Time to all-cause mortality and
ime to first cardiovascular hospitalization were similar in
he enoximone and placebo study groups (hazard ratios 0.97
nd 0.98, respectively). Interestingly, both all-cause mortal-
ty and mortality or cardiovascular hospitalization rates were
ower with enoximone in the last one-half of follow-up
beyond 16.4 months) (5.4% with enoximone vs. 8.8% with
lacebo, p  0.045; and 12.5% with enoximone vs. 17.4%
ith placebo; p  0.09). Furthermore, patients with LVEF
20% had greater improvement in 6-min walk test distance
n the enoximone group (55). High hopes have also been
laced on the results of the two phase III trials on another
nodilator drug, levosimendan. Results of two prospective
rials, Survival in Patients with Acute Heart Failure in Need
f Intravenous Inotropic Support (SURVIVE) and Second
andomized Multicenter Evaluation of Intravenous Levo-
imendan Efficacy Versus Survival in the Short Term
reatment of Decompensated Heart Failure (REVIVE-II)
56) will be presented at the upcoming AHA Scientific
essions.
anthine oxidase inhibition. Another novel target that
as been tested in patients with advanced HF involves
nhibition of xanthine oxidase. Small observational trials
ad previously shown that allopurinol, a known inhibitor of
anthine oxidase, is associated with improvement in endo-
helial function and exercise capacity in patients with HF.
xypurinol, an active derivative of allopurinol, has been
eveloped as a potential oral therapy for patients with
dvanced HF. However, results of the phase II Oxypurinol
herapy for Congestive Heart Failure OPT-CHF (OPT-
HF) study (57) were somewhat disappointing, as the
reliminary analysis suggested no added benefit. This fol-
ows in the footsteps of unsuccessful attempts to block
pecific anti-inflammatory pathways with anticytokine ther-
py in HF. All hopes are currently focused on two new
trategies, a novel non-pharmacologic form of immune
odulation therapy (Celacade, Vasogen Inc., Mississauga,
ntario, Canada) (58), and statin therapy (59)—both
trategies are currently undergoing multicenter phase III
ortality trials (Advanced Chronic Heart Failure Clinical
ssessment of Immune Modulation Therapy [AD-
ANCED] and Controlled Rosuvastatin Multinational
tudy in Heart Failure [CORONA], respectively).
urgical therapies for HF. There were several controver-
ial developments in the area of surgical therapies for HF
ping Worsening Renal Function (50,51)
volved HR (95% CI) p Value
OACTION 1.74 (0.97–3.12) 0.059
NT, 311, 325, 326 1.54 (1.20–1.99) 0.001
2.29 (1.07–4.89) 0.03
1.18 (0.50–2.76) 0.71evelo
als In
C, PR
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26his year. The CorCap Cardiac Support Device (CSD) is a
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The Year in Heart Failure December 6, 2005:2125–33roprietary mesh wrap that is implanted around the heart to
ttenuate cardiac remodeling. The 300-subject multicenter
ssessment of a CSD in Patients With Heart Failure
ACORN) trial was announced in November 2004 at the
HA Scientific Sessions. In comparison with control pa-
ients, patients with CorCap CSD demonstrated sustained
mprovements in cardiac structure and function, significant
mprovements in quality of life, and a 50% relative reduction
n need for additional cardiac procedures for worsening HF
uch as transplant or implants of ventricular assist or
lectrical stimulation devices (60). Although a U.S. Food
nd Drug Administration external advisory board found the
ata to be less than robust, there is still hope that this
ardiac support device may find its way to the market.
While long-term experience with surgical ventricular
estoration surgery for post-infarction ventricular dilatation
ppears to be favorable (61), the role of mitral valve repair in
he case of patients with severe HF is being challenged. A
arge surgical series found no clearly demonstrable long-
erm mortality benefit conferred by mitral valve annulo-
Figure 2. Primary results of the Cardiac Resynchronization inlasty for significant mitral regurgitation with severe left aentricular dysfunction (62). Further studies are still neces-
ary to better define the responder population.
Stem cell therapy remains an exciting area of research,
ith the use of a wide range of stem/progenitor cell types for
he regeneration of the infarcted heart (including embryonic
tem cells, hematopoietic stem and progenitor cells, mesen-
hymal stem and progenitor cells, as well as resident cardiac
stem” cells). Different strategies have also been developed
o manipulate cardiomyocyte cell growth in vitro for its use
n HF. The current status of this field involves many
ifferent types of regenerating cells. The delivery of these
ells varies widely, and long-term experience for autologous
keletal myoblast and progenitor cell transplant in patients
ith ischemic cardiomyopathy has been reassuring (63–66).
OLE OF DEVICE THERAPIES FOR HF
ardiac resynchronization therapy (CRT). Cardiac re-
ynchronization therapy has received another round of
Failure trial (CARE-HF). Reproduced with permission (67).cceptance with the presentation and publication of the
l
c
8
s
fi
p
Q
p
n
t
d
o
H
t
f
(
i
(
C
s
c
d
R
t
I
p
a
t
w
B
m
t
c
p
t
p
m
H
f
s
t
c
t
R
i
W
s
C
d
h
t
n
i
r
S
T
t
a
u
t
e
p
e
w
H
p
N
a
t
R
D
d
t
R
1
1
1
2131JACC Vol. 46, No. 11, 2005 Tang and Francis
December 6, 2005:2125–33 The Year in Heart Failurearge-scale mortality European trial, the Cardiac Resyn-
hronization in Heart Failure (CARE-HF) study. This
13-patient, well-designed, randomized study is the first to
how benefit with CRT with respect to survival, and the
rst to show benefit and continued improvement for a
eriod of over two years in patients with LVEF 35% and
RS duration 120 ms (Fig. 2) (67). Remarkably, 255
atients randomized to the CRT arm had complete or
ear-complete resolution of their symptoms, 57 CRT pa-
ients had LVEF 40% at the 18-month follow-up. These
ata, in combination with the CRT arm of the Comparison
f Medical Therapy, Pacing, and Defibrillation in Chronic
eart Failure (COMPANION) trial, clearly demonstrated
he mortality benefits of CRT. Furthermore, CRT has been
ound to be cost effective in managing advanced HF patients
68), and reverse remodeling by CRT may directly lead to
mproved survival independent of symptomatic benefits
69). However, the criteria used in selecting patients for
RT continue to evolve with the broad availability of tissue
ynchronization echocardiography and better defined echo-
ardiographic measurements of inter- and intraventricular
elay. The ongoing Predictors of Response to Cardiac
esynchronization Therapy (PROSPECT) trial is designed
o address optimal patient selection (70).
CDs. Primary prevention of sudden cardiac death in
atients with HF has been the center of attention after the
nnouncement of clinical indications for ICD therapy by
he Centers for Medicare and Medicaid Services and the
ide endorsement of the ACC/AHA guidelines (40).
eyond all traditional indications, all patients with prior
yocardial infarction and LVEF 30% (Multicenter Au-
omatic Defibrillator Implantation Trial-2 [MADIT-2]
riteria), symptomatic (NYHA functional class II to III)
atients with prior myocardial infarction and LVEF of 30%
o 35%, or symptomatic (NYHA functional class II to III)
atients with non-ischemic cardiomyopathy for over nine
onths with LVEF 35% (Sudden Cardiac Death in
eart Failure Trial [SCD-HeFT] criteria) may also qualify
or ICD. Nevertheless, physicians should tailor their discus-
ion with their patients about the risks and benefits of ICD
herapy in the context of their expectations for their HF
ondition in order to best utilize this life-saving (and costly)
herapy.
hythm control in atrial fibrillation. New evidence favor-
ng rhythm control with atrial fibrillation has emerged (71).
hile rate control may not be inferior to rhythm control, a
ubset of subjects in the Rate Control versus Electrical
ardioversion (RACE) study with mild-to-moderate HF
emonstrated higher rates of cardiovascular death, HF
ospitalization, and bleeding in the rate control compared
o the rhythm control group (72). Catheter ablation tech-
iques for rhythm control (such as pulmonary vein isolation)
n this population are particularly promising (73,74), but the
elative risks versus benefits remain to be determined.UMMARY AND CONCLUSIONS
he rate of generation of new knowledge and expansion of
herapeutic approaches to the diagnosis and treatment of
cute and chronic HF continues to be dramatic. Recent
pdates of major clinical guidelines have facilitated the
ranslation of clinical evidence into everyday practice. How-
ver, as more and more options become available for this
atient population, resource allocation and cost-
ffectiveness become challenging issues. Device therapies
ill continue to evolve with newer and broader indications.
owever, there are still major knowledge gaps regarding the
rediction of treatment response and disease progression.
ew concepts in HF therapeutics (such as NO homeostasis
nd renal preservation) will need rigorous testing, and
raditional strategies should continue to be challenged.
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